ExpreS2ion’s Chief Scientific Officer, Dr. Wian de Jongh, is Appointed Affiliated Associate Professor at the Technical University of Denmark
Horsholm, Denmark, February 14, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is appointed the honorary position of affiliated associate professor at the Technical University of Denmark (“DTU”). The position is for a duration of five years, commencing in February 2017.
The affiliated associate professor appointment
The position as affiliated associate professor at DTU for a period of five years starting in February 2017 is an honorary position that the president of DTU, Professor Anders Bjarklev, has offered Dr. Wian de Jongh, CSO at ExpreS2ion, based on a recommendation from DTU Bioengineering and is unanimously approved by the Senate of the University.
CSO Wian de Jongh comments
“It is with pleasure and great honour that I am accepting the position as affiliated associate professor at DTU. I have had a fantastic journey with this university, from my own student days to my current role as CSO of ExpreS2ion. I look forward to continued collaborations with DTU over the next five years”.
CEO Steen Klysner comments
“I congratulate Dr. de Jongh with his appointment to affiliated associate professor at DTU which also is a testament to ExpreS2ion engagement in the forefront of bioengineering research with strong links to academia. Dr. de Jongh is co-inventor of the technology platform that is the foundation of ExpreS2ion and I am delighted to have a capacity as Dr. de Jongh in the company’s management team, ensuring a strong R&D profile.”
For further information, please contact:
ExpreS2ion Biotechnologies, Steen Klysner, CEO
Telephone: 45 2062 9908
E-mail: sk@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS, is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique platform technology, ExpreS2, enabling cost effective development and robust production of complex proteins for new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the company has used its patented ExpreS2platform to produce more than 200 proteins in collaborations with research institutions and biopharmaceutical companies, with a superior efficiency and success rate.
Tags: